IN THE CLAIMS

1. (canceled).

2. (Previously presented) A compound of formula (I)



(I)

wherein:

R^1 is selected from:

a) phenyl, which is optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, CF_3, halo, CN, NR^7R^8, SO_2R^6 and OC_1-C_6 alkyl, and

b) Aromatic Heterocycle, wherein said Aromatic Heterocycle is selected from pyridyl, pyrazinyl, pyrimidinyl, quinolinyl, quinoxalinyl, isoxazolyl and pyrazolyl, each aromatic heterocycle optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, SR^6, SO_2R^6, NH_2, CF_3, halo, OH, OC_1-C_6 alkyl, NR^7R^8 wherein R^8 may be optionally substituted by NH_2, phenyl or Heterocycle, and OPh wherein Ph may be optionally substituted by 1-3 groups each independently selected from halo and C_1-C_6 alkyl;

R^2 is selected from:

a) phenyl, which is optionally substituted by methyl, fluoro, chloro, methoxy, CF_3 or SO_2CH_3,

b) pyrazolyl, which is optionally substituted by methyl, and

c) $C(O)N(CH_3)_2$;

R^3 is selected from:

a) phenyl, said phenyl being optionally fused to Heterocycle and said phenyl or said fused phenyl being optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, halo, CN and OC_1-C_6 alkyl,

b) R^6,

c) cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, which is optionally substituted by C_1-C_6 alkyl; and

d) Aromatic Heterocycle, wherein said Aromatic Heterocycle may be defined as a 5-6 membered aromatic heterocycle containing 1 or 2 nitrogen atoms, said ring optionally fused with a phenyl or a 3-8 membered cycloalkyl group.

R^4 is H;

R^5 is $CONH_2$;

R^6 is methyl;

R^7 is hydrogen or C_1-C_6 alkyl;

R^8 is C_1-C_6 alkyl;

or NR^7R^8 forms a monocyclic saturated ring system containing between 3 and 7 ring atoms;

x is 1;

y is 0; and

z is 0 or 1

wherein:

Aromatic Heterocycle may be defined as a 5-6 membered aromatic heterocycle containing 1-4 heteroatoms each independently selected from N, O and S, said ring optionally fused with a phenyl or a 3-8 membered cycloalkyl group;

Heterocycle is a 5-8 membered saturated or partially saturated ring containing 1-3 heteroatoms each independently selected from N, O and S, said ring optionally fused with phenyl;

a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer.

2 ~~3~~. (Currently amended) A compound according to claim ~~2~~ 1 wherein R^1 is selected from:

a) phenyl, which is optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, CF_3, halo, CN, NR^7R^8, SO_2R^6 and OC_1-C_6 alkyl, and

b) Aromatic Heterocycle, wherein said Aromatic Heterocycle is selected from:

i) pyridyl, which is optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, SO_2R^6, NH_2, CF_3, CN, halo, OH, OC_1-C_6 alkyl, NR^7R^8 wherein R^8 may be optionally substituted by NH_2, phenyl or Heterocycle, and OPh wherein Ph may be optionally substituted by 1-3 groups each independently selected from halo and C_1-C_6 alkyl;

ii) pyrimidinyl, which is optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, SO_2R^6, NH_2, CF_3, CN, halo, OH, OC_1-C_6 alkyl, NR^7R^8 wherein R^8 may be optionally substituted by NH_2, phenyl or Heterocycle, and OPh wherein Ph may be optionally substituted by 1-3 groups each independently selected from halo and C_1-C_6 alkyl;

iii) pyrazinyl, which is optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, NH_2, SR^6 and halo;

iv) quinolinyl;

v) quinoxalinyl, which is optionally substituted by OH;

vi) isoxazolyl, which is optionally substituted by 1-3 groups each independently selected from: C_1-C_6 alkyl; and

vii) pyrazole;

~~R^2 is selected from:~~

~~a) phenyl, which is optionally substituted by methyl, halo, methoxy, CF_3 or SO_2CH_3;~~

~~b) cyclopropyl or 1- or 2-indanyl;~~

~~c) pyrazolyl, which is optionally substituted by methyl;~~

~~d) $C(O)N(CH_3)_2$; and~~

~~e) piperidinyl substituted by $C(O)R^6$.~~

R^3 is selected from:

a) phenyl, said phenyl being optionally fused to 1,4-dioxan and said phenyl or said fused phenyl being optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, halo, CN and OC_1-C_6 alkyl;

b) R^6,

c) cyclopropyl, which is optionally substituted by C_1-C_6 alkyl; and

d) Aromatic Heterocycle, wherein said Aromatic Heterocycle is selected from pyrazolyl or pyridyl, both optionally substituted by C_1-C_6 alkyl;

~~R^5 is $CONH_2$ or CH_3;~~ and

z is 0.

~~4.~~ 3 (Currently amended) A compound according to any one of claims ~~1 to~~ ~~2~~ 1 or ~~3~~ 2 wherein R^1 is phenyl, 2- or 3-pyridyl or 2,4-pyrimidinyl, said moieties being optionally substituted by 1-3 groups each independently selected from C_1-C_6 alkyl, halo, OC_1-C_6 alkyl, CN, SO_2R^6, NHR_7, $NHCH_2CH_2NH_2$ and CF_3;

~~5.~~ 4 (original) A compound according to claim ~~4~~ 3 wherein R^1 is phenyl, 2- or 3-pyridyl or 2,4-pyrimidinyl, said moieties being optionally substituted by 1-3 groups each independently selected from methyl, fluoro, chloro, methoxy, ethoxy, n-propoxy, CN, SO_2CH_3, NH_2, $NHCH_3$, $NHCH_2CH_2NH_2$, and CF_3.

6. (canceled)

~~7.~~ 5 (previously presented) A compound according to claim ~~6~~ 4 wherein R^2 is phenyl, *para*-fluorophenyl, *para*-chlorophenyl, *para*-methylphenyl, 2,5-dimethylphenyl, *o*-methylphenyl and *para*-methoxyphenyl.

~~8.~~ 6 (previously presented) A compound according to claim ~~7~~ 5 wherein R^3 is selected from:

a) phenyl, said phenyl being optionally fused to 1,4-dioxan and said phenyl or said fused phenyl being optionally substituted by 1-2 groups each independently selected from methyl, methoxy, ethoxy, fluoro, chloro and CN;

b) isopropyl;

c) cyclopropyl; and

d) pyrazolyl and pyridyl, both optionally substituted by methyl.

9. (original) A compound according to claim 6 wherein R^3 is 3-methoxyphenyl or 1,4-benzodioxanyl.

10. (Cancelled).

11. (Previously presented) A compound according to claim 1 selected from:

2-Amino-*N*-[2-amino-1-(2-methylphenyl)-2-oxoethyl]-*N*-(4-chlorobenzyl)nicotinamide,

N-[2-Amino-1-(3-methoxyphenyl)-2-oxoethyl]-4-cyano-*N*-(4-methylbenzyl)benzamide,

N-[3-Amino-1-(3-methoxyphenyl)-3-oxopropyl]-4-methyl-*N*-(4-methylbenzyl)nicotinamide,

2-Amino-*N*-[(1*S*)-3-amino-3-oxo-1-phenylpropyl]-*N*-(4-methylbenzyl)nicotinamide,

5-Chloro-2-methylthio-N-[2-amino-1-{1,4-benzodioxan-6-yl}-2-oxoethyl]-N-(4-methylbenzyl)pyrimidine-4-carboxamide,

5-Chloro-2-amino-N-[2-amino-1-{1,4-benzodioxan-6-yl}-2-oxoethyl]-N-(4-methylbenzyl)pyrimidine-4-carboxamide, and

2-Amino-N-[carbamoyl-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-methyl]-4,6-dimethyl-N-(4-methyl-benzyl)-nicotinamide;

and tautomers thereof and pharmaceutically acceptable salts, solvates and polymorphs of said compound or tautomer.

12. (Previously presented) A pharmaceutical composition comprising a compound of claim 1, or pharmaceutically acceptable salts, solvates or polymorphs thereof, and a pharmaceutically acceptable diluent or carrier.

13. (previously canceled)

14. (Previously presented) A method of treatment of a disorder or condition where inhibition of Oxytocin is known, or can be shown, to produce a beneficial